Lead: GLP-1 medications such as Novo Nordisk’s semaglutide (Ozempic/Wegovy) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound) have moved from specialist clinics into mainstream conversation — so much so that “Ozempic face” was shortlisted as a word-of-the-year candidate in 2025. These drugs, prescribed mainly for Type 2 diabetes and now for obesity in several formulations, act on appetite and blood-sugar control and carry similar gastrointestinal side effects and class warnings. Approvals and formulations vary: some are once-weekly injections, others are daily pills or injections, and new oral and multi-hormone agents are expected in 2026. This guide explains current options, safety notes, and what to watch for next.
Key Takeaways
- Semaglutide (Ozempic/Wegovy): FDA approved for Type 2 diabetes in 2017 (Ozempic) and for obesity as Wegovy in 2021; a once-daily semaglutide pill formulation gained FDA clearance in December 2025.
- Tirzepatide (Mounjaro/Zepbound): Mounjaro cleared for Type 2 diabetes in 2022 and Zepbound for obesity in 2023; both use once-weekly injections with identical dosing schedules.
- Liraglutide (Victoza/Saxenda): Victoza approved in 2010 for diabetes and Saxenda in 2014 for obesity; generic versions were approved in 2024 (Victoza) and 2025 (Saxenda).
- Dulaglutide (Trulicity) has been available since 2014 for Type 2 diabetes as a weekly injection and is not approved for weight loss.
- Exenatide was the first GLP-1 approved in 2005; several AstraZeneca formulations were withdrawn in recent U.S. markets, while a generic Byetta was approved in late 2024.
- Lixisenatide (Adlyxin) arrived in 2016 and was discontinued in the U.S. in 2023 but remains available in other markets (Lyxumia) and in combination products such as Soliqua.
- New oral and multi-receptor drugs are approaching the market: Lilly’s orforglipron (oral, nonpeptide) targets mid-to-late 2026 launches and retatrutide (GLP-1/GIP/glucagon) is expected for regulatory submission in 2026.
- Class-wide warnings exist for those with personal/family histories of medullary thyroid carcinoma (MTC) or MEN 2; common side effects across agents are gastrointestinal (nausea, vomiting, diarrhea, constipation).
Background
GLP-1 receptor agonists were developed to harness a gut hormone pathway that boosts insulin secretion when glucose is elevated and slows gastric emptying to blunt post-meal blood-sugar spikes. The class has expanded from injectable peptides used for Type 2 diabetes to higher-dose formulations for obesity and, more recently, to oral options designed to improve convenience and uptake.
Regulatory approvals have driven growing public awareness. Semaglutide-based products became especially prominent after Wegovy’s obesity indication, and news coverage of weight-loss effects pushed GLP-1s into mainstream conversation by the mid-2020s. That attention has raised demand, supply questions and debate about off-label use, equity of access, and long-term safety monitoring.
Pharmaceutical companies continue to develop next-generation agents that act on additional metabolic hormones (GIP, glucagon) or use small-molecule chemistry to make oral dosing feasible. These advances could widen treatment choices for clinicians and patients but also complicate prescribing decisions because each molecule differs in mechanism, dosing cadence and regulatory indications.
Main Event
Semaglutide is among the most recognized GLP-1s. Ozempic (semaglutide for Type 2 diabetes) was FDA-approved in 2017; Wegovy, a higher-dose semaglutide formulation for chronic weight management, received an obesity indication in 2021. In December 2025 the FDA approved a once-daily oral form of the higher-dose semaglutide (a pill marketed alongside existing injectables), expanding routes of administration for the same active compound.
Tirzepatide, developed by Eli Lilly, is distinct because it activates two incretin pathways: GLP-1 and GIP. Mounjaro (tirzepatide) won FDA approval for Type 2 diabetes in 2022 and the obesity formulation Zepbound followed in 2023. Both are administered as once-weekly injections with identical dosing schedules, and no FDA-approved generic tirzepatide exists at this time.
Liraglutide-based treatments (Victoza for diabetes, Saxenda for obesity) have been on the market for over a decade. Victoza was cleared in 2010 and Saxenda in 2014; generic versions of each were approved in 2024 and 2025 respectively. Dulaglutide (Trulicity) is another weekly injectable approved in 2014 for glucose control, though it is not labeled for weight loss.
Earlier entrants like exenatide were pioneering: first FDA approval in 2005 introduced Byetta (twice-daily) and weekly formulations under the Bydureon name. AstraZeneca later withdrew several exenatide formulations from the U.S. market, but a generic Byetta was approved by the FDA in late 2024. Lixisenatide (Adlyxin) — approved in 2016 — was discontinued in the U.S. in 2023, yet the molecule persists internationally and in combination products.
Analysis & Implications
Clinical implications are twofold: metabolic disease management and expansion into obesity treatment. For patients with Type 2 diabetes, GLP-1s offer meaningful HbA1c reduction combined with weight benefits for many agents. For obesity care, dedicated higher-dose formulations demonstrated weight-loss efficacy that changed treatment paradigms and influenced healthcare demand patterns in primary care and specialty clinics.
However, wider use raises access and equity issues. Insurance coverage for obesity indications varies by payer and geography, and the arrival of oral and new multi-receptor drugs will likely intensify formulary negotiation and prescribing complexity. Generics entering the market (as with liraglutide generics in 2024–2025 and exenatide generics) may improve affordability but transition timelines and uptake are uneven.
Safety monitoring remains essential. The class has consistent gastrointestinal side effects, and several agents carry boxed warnings from rodent findings linking them to thyroid C-cell tumors; regulators recommend avoiding use in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Long-term human data are still accumulating for newer molecules, so clinicians emphasize shared decision-making and routine surveillance where indicated.
Comparison & Data
| Drug (Example Brands) | First FDA Approval Year | Typical Dosing Form | Primary U.S. Indications |
|---|---|---|---|
| Semaglutide (Ozempic, Wegovy, Rybelsus) | 2017 (Ozempic), 2019 (Rybelsus), 2021 (Wegovy) | Weekly injection; daily oral for Rybelsus and oral Wegovy (Dec 2025) | Type 2 diabetes, obesity (Wegovy) |
| Tirzepatide (Mounjaro, Zepbound) | 2022 (Mounjaro), 2023 (Zepbound) | Weekly injection | Type 2 diabetes, obesity (Zepbound) |
| Liraglutide (Victoza, Saxenda) | 2010 (Victoza), 2014 (Saxenda) | Daily injection | Type 2 diabetes, obesity (Saxenda) |
| Dulaglutide (Trulicity) | 2014 | Weekly injection | Type 2 diabetes |
| Exenatide (Byetta, Bydureon) | 2005 | Twice-daily or weekly injection (formulations varied) | Type 2 diabetes |
Context: The table highlights differences in route, cadence and indication that matter for patients and prescribers. Oral options reduce injection barriers but may differ in tolerability or dosing. Multi-receptor agents could shift efficacy and side-effect profiles compared with single-receptor GLP-1 agonists.
Reactions & Quotes
Regulators and industry stakeholders have framed recent approvals as incremental advances in care while urging continued post-market observation.
“These approvals expand treatment choices for clinicians and patients managing diabetes and obesity,”
FDA statement on GLP-1 approvals (paraphrased)
Patient groups and some clinicians emphasize access concerns and the need for clear guidance on long-term use.
“Greater availability is promising, but equitable coverage and longer-term safety data are essential,”
Obesity advocacy group (paraphrased)
Researchers tracking next-generation molecules note the scientific interest in oral small molecules and triple-agonists as potential shifts in treatment strategy.
“Combining hormonal pathways or enabling oral dosing could broaden who benefits from metabolic drugs,”
Academic endocrinologist (paraphrased)
Unconfirmed
- Long-term cardiovascular and oncologic risks specific to newer dual- or triple-agonists remain under study and are not yet settled.
- Market timing for every pipeline drug is subject to regulatory review schedules; launch windows (mid-to-late 2026) are projections based on company guidance and could shift.
- Real-world durability of weight loss for newer agents beyond trial durations is still being evaluated.
Bottom Line
GLP-1 receptor agonists and related incretin-based drugs have reshaped diabetes care and are now central to many obesity-treatment conversations. Different molecules vary by mechanism, dosing frequency and approved uses; those distinctions affect tolerability, monitoring needs and insurance coverage.
New oral formulations and multi-hormone agents expected to reach regulators in 2026 could broaden options but will add complexity to prescribing and coverage decisions. Clinicians should evaluate each patient’s cardiovascular risk, cancer family history (notably MTC/MEN 2), kidney function and treatment goals when choosing a therapy.